D. MITCHELL,* K. P. COLE, P. M. POLLOCK, D. M. COPPERT, T. P. BURKHOLDER,
J. R. CLAYTON (ELI LILLY AND COMPANY, INDIANAPOLIS, USA)
Development and a Practical Synthesis of the JAK2 Inhibitor LY2784544
Org. Process Res. Dev. **2012**, *16*, 70–81.

Synthesis of LY2784544

Significance: LY2784544 is a Janus kinase 2 (JAK2) inhibitor that is under development for the treatment of myeloproliferative neoplasms. The synthesis depicted delivered >100 kg of the target molecule and features a new aminomethylation reaction (**E** → **G**) involving *N*-methylmorpholine *N*-oxide and vanadium catalysis.

Comment: The authors speculate that the aminomethylation reaction of **E** involves a primary radical derived from *N*-methylmorpholine. An alternative ionic mechanism based on an iminium salt is unlikely since *N*-methylenmorpholinium chloride reacts preferentially at the methyl group in **E** (Mannich-type reaction).

SYNFACTS Contributors: Philip Kocienski
Synfacts 2012, 8(4), 0351 Published online: 20.03.2012
DOI: 10.1055/s-0031-1290309; **Reg-No.:** K01112SF

2012 © THIEME STUTTGART • NEW YORK

Category

Synthesis of Natural
Products and
Potential Drugs

Key words

LY2784544

Janus kinase
inhibitors

vanadium catalysis

aminomethylation

N-arylation

SYNFACTS
of the month

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.